metformin has been researched along with Animal Mammary Carcinoma in 14 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we used an 1-methyl-1-nitrosourea (MNU)-induced mammary tumor rat model of estrogen receptor (ER)-positive postmenopausal breast cancer to evaluate the long-term effects of metformin administration on metabolic and tumor endpoints." | 7.88 | Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. ( Anderson, SM; Edwards, DP; Giles, ED; Jindal, S; MacLean, PS; Schedin, P; Schedin, T; Thor, AD; Wellberg, EA, 2018) |
| " In the present study, the effect of long-term administration of peroral antidiabetic metformin and pineal hormone melatonin on liver antioxidant and aerobic status in female Sprague-Dawley rats carrying mammary tumors induced by N-methyl-N-nitrosourea was evaluated." | 5.48 | Liver antioxidant and aerobic status improves after metformin and melatonin administration in a rat model of high-fat diet and mammary carcinogenesis. ( Bojková, B; Kurhaluk, N; Winklewski, PJ, 2018) |
| "Here, we used an 1-methyl-1-nitrosourea (MNU)-induced mammary tumor rat model of estrogen receptor (ER)-positive postmenopausal breast cancer to evaluate the long-term effects of metformin administration on metabolic and tumor endpoints." | 3.88 | Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. ( Anderson, SM; Edwards, DP; Giles, ED; Jindal, S; MacLean, PS; Schedin, P; Schedin, T; Thor, AD; Wellberg, EA, 2018) |
| "Metformin treatment of the diabetic/obese mice effectively normalized glucose levels, reconfigured the mammary tumor milieu, and decreased metastatic seeding." | 1.62 | Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. ( Alsheikh, HAM; Ha, CM; Hinshaw, DC; Kammerud, SC; Lama-Sherpa, T; Metge, BJ; Mota, MSV; Samant, RS; Sharafeldin, N; Shevde, LA; Wende, AR, 2021) |
| "The treatment with metformin and LY294002 was able to reduce the cellular viability after 24 hours." | 1.51 | Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor. ( Borin, TF; Carvalho, LGS; de Campos Zuccari, DAP; Ferreira, LC; Gelaleti, GB; Hellmén, E; Jardim-Perassi, BV; Leonel, C; Maschio-Signorini, LB; Moschetta, MG; Sonehara, NM, 2019) |
| " In the present study, the effect of long-term administration of peroral antidiabetic metformin and pineal hormone melatonin on liver antioxidant and aerobic status in female Sprague-Dawley rats carrying mammary tumors induced by N-methyl-N-nitrosourea was evaluated." | 1.48 | Liver antioxidant and aerobic status improves after metformin and melatonin administration in a rat model of high-fat diet and mammary carcinogenesis. ( Bojková, B; Kurhaluk, N; Winklewski, PJ, 2018) |
| "Metformin has demonstrated anti-tumorigenic effect both in vivo and in vitro in different cancer types." | 1.46 | Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. ( Abo Mansour, HE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, NF, 2017) |
| "Metformin treatment reduced N-cadherin and increased E-cadherin expression in both CF41 and TGF-β1sh cells." | 1.46 | Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. ( Bajgelman, MC; Borin, TF; de Campos Zuccari, DA; de Carvalho Ferreira, L; Leonel, C; Moschetta, MG; Viloria-Petit, AM, 2017) |
| "Metformin is an oral hypoglycaemic drug used in type 2 diabetes." | 1.42 | Anti-tumour effect of metformin in canine mammary gland tumour cells. ( Fujita, N; Matsumoto, K; Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Saito, T; Sugano, S; Tanaka, Y; Tsuboi, M; Watanabe, M; Yoshitake, R, 2015) |
| "The treatment with melatonin alone (2 mg/L in drinking water during the night time) or combined treatment with metformin (0." | 1.36 | Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. ( Anikin, IV; Anisimov, VN; Egormin, PA; Karkach, AS; Piskunova, TS; Popovich, IG; Romanyukha, AA; Tyndyk, ML; Yurova, MN; Zabezhinski, MA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S | 1 |
| Ruiz-Calderon, B | 1 |
| Rathinam, R | 1 |
| Eastlack, S | 1 |
| Maziveyi, M | 1 |
| Alahari, SK | 1 |
| Alsheikh, HAM | 1 |
| Metge, BJ | 1 |
| Ha, CM | 1 |
| Hinshaw, DC | 1 |
| Mota, MSV | 1 |
| Kammerud, SC | 1 |
| Lama-Sherpa, T | 1 |
| Sharafeldin, N | 1 |
| Wende, AR | 1 |
| Samant, RS | 1 |
| Shevde, LA | 1 |
| El-Ashmawy, NE | 1 |
| Khedr, NF | 1 |
| El-Bahrawy, HA | 1 |
| Abo Mansour, HE | 1 |
| Arbe, MF | 1 |
| Fondello, C | 1 |
| Agnetti, L | 1 |
| Álvarez, GM | 1 |
| Tellado, MN | 1 |
| Glikin, GC | 1 |
| Finocchiaro, LME | 1 |
| Villaverde, MS | 1 |
| Kurhaluk, N | 1 |
| Bojková, B | 1 |
| Winklewski, PJ | 1 |
| Giles, ED | 1 |
| Jindal, S | 1 |
| Wellberg, EA | 1 |
| Schedin, T | 1 |
| Anderson, SM | 1 |
| Thor, AD | 1 |
| Edwards, DP | 1 |
| MacLean, PS | 1 |
| Schedin, P | 1 |
| Yeo, SK | 1 |
| Paul, R | 1 |
| Haas, M | 1 |
| Wang, C | 1 |
| Guan, JL | 1 |
| Moschetta, MG | 2 |
| Leonel, C | 2 |
| Maschio-Signorini, LB | 1 |
| Borin, TF | 2 |
| Gelaleti, GB | 1 |
| Jardim-Perassi, BV | 1 |
| Ferreira, LC | 1 |
| Sonehara, NM | 1 |
| Carvalho, LGS | 1 |
| Hellmén, E | 1 |
| de Campos Zuccari, DAP | 1 |
| Shehata, M | 1 |
| Kim, H | 1 |
| Vellanki, R | 1 |
| Waterhouse, PD | 1 |
| Mahendralingam, M | 1 |
| Casey, AE | 1 |
| Koritzinsky, M | 1 |
| Khokha, R | 1 |
| Barbieri, F | 1 |
| Thellung, S | 1 |
| Ratto, A | 1 |
| Carra, E | 1 |
| Marini, V | 1 |
| Fucile, C | 1 |
| Bajetto, A | 1 |
| Pattarozzi, A | 1 |
| Würth, R | 1 |
| Gatti, M | 1 |
| Campanella, C | 1 |
| Vito, G | 1 |
| Mattioli, F | 1 |
| Pagano, A | 1 |
| Daga, A | 1 |
| Ferrari, A | 1 |
| Florio, T | 1 |
| Saeki, K | 1 |
| Watanabe, M | 1 |
| Tsuboi, M | 1 |
| Sugano, S | 1 |
| Yoshitake, R | 1 |
| Tanaka, Y | 1 |
| Ong, SM | 1 |
| Saito, T | 1 |
| Matsumoto, K | 1 |
| Fujita, N | 1 |
| Nishimura, R | 1 |
| Nakagawa, T | 1 |
| de Carvalho Ferreira, L | 1 |
| Bajgelman, MC | 1 |
| Viloria-Petit, AM | 1 |
| de Campos Zuccari, DA | 1 |
| Anisimov, VN | 2 |
| Egormin, PA | 2 |
| Piskunova, TS | 2 |
| Popovich, IG | 2 |
| Tyndyk, ML | 1 |
| Yurova, MN | 1 |
| Zabezhinski, MA | 1 |
| Anikin, IV | 1 |
| Karkach, AS | 1 |
| Romanyukha, AA | 1 |
| Bershtein, LM | 1 |
| Zabezhinskii, MA | 1 |
| Semenchenko, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 other studies available for metformin and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
Topics: Animals; Antigens, Polyomavirus Transforming; Cell Transformation, Neoplastic; Female; Hypoglycemic | 2020 |
Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Mellitus, Experimental; Female; | 2021 |
Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell | 2017 |
Inhibition of bioenergetic metabolism by the combination of metformin and 2-deoxyglucose highly decreases viability of feline mammary carcinoma cells.
Topics: Animals; Antineoplastic Agents; Cats; Cell Line, Tumor; Cell Survival; Deoxyglucose; Energy Metaboli | 2017 |
Liver antioxidant and aerobic status improves after metformin and melatonin administration in a rat model of high-fat diet and mammary carcinogenesis.
Topics: Aerobiosis; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Carcinogenesis | 2018 |
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Topics: Animals; Aromatase; Breast; Breast Neoplasms; Disease Progression; Estrogen Receptor alpha; Female; | 2018 |
Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Benzylamines; BRCA1 Protein; Cell Line, Tumor; Disea | 2018 |
Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor.
Topics: Animals; Cell Line, Tumor; Chromones; Cobalt; Dog Diseases; Dogs; Female; Hypoxia-Inducible Factor 1 | 2019 |
Identifying the murine mammary cell target of metformin exposure.
Topics: Animals; Apoptosis; Cell Cycle; Cell Lineage; Cell Separation; DNA Damage; Female; Flow Cytometry; H | 2019 |
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2015 |
Anti-tumour effect of metformin in canine mammary gland tumour cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Survival; Dog Diseases; Dogs; Female; | 2015 |
Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model.
Topics: Animals; Cadherins; Cell Line, Tumor; Cell Movement; Dogs; Epithelial-Mesenchymal Transition; Mammar | 2017 |
Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.
Topics: Adenocarcinoma; Age Factors; Animals; Female; Longevity; Male; Mammary Neoplasms, Animal; Melatonin; | 2010 |
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.
Topics: Adenocarcinoma; Animals; Female; Homozygote; Hypoglycemic Agents; Longevity; Mammary Neoplasms, Anim | 2005 |